ArticleIndian journal of endocrinology and metabolism
Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD).
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There is a rising prevalence of metabolic-associated steatotic liver disease (MASLD), particularly in patients with type 2 diabetes mellitus, which needs early detection and treatment to prevent the grave outcomes. Dapagliflozin and Saroglitazar are known to improve metabolic and liver health in patients with type 2 diabetes mellitus. Methods: Our study was a randomised, controlled, open-label, parallel trial of 101 patients with T2DM and MASLD. Patients were randomly assigned to receive Dapagliflozin 10 mg or Saroglitazar 4 mg on top of standard diabetes care. The primary endpoints were changes in hepatic steatosis and fibrosis (FIB) as estimated by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) using FibroScan, respectively. The secondary endpoints were changes in anthropometric parameters, glycemic parameters, lipid profiles, transaminases, and FIB scores, which were monitored at baseline, 3 months, and 6 months. Results: At the end of 6 months of study, both cohorts resulted in significant clinical benefits. Comparison between the two cohorts revealed no significant statistical difference between the two groups regarding their impact on the primary endpoints (CAP and LSM). Minimal but statistically significant intergroup differences were noted only for BMI ( Conclusion: Both Dapagliflozin and Saroglitazar are potent therapeutic options in patients with type 2 diabetes mellitus who also have MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.